#United States #cancer therapy #Princeton #Ymmunobio #YB-800

Ymmunobio and PSI: Pioneering Cancer Treatment with Radio-Pharmaceutical YB-800

Ymmunobio, an innovator in the field of oncology, has recently announced a collaborative project with the Paul Scherrer Institute (PSI), receiving crucial support from Innosuisse to advance its cutting-edge radio-pharmaceutical, YB-800. This initiative aims to develop groundbreaking radioactive-loaded antibodies targeted for both the treatment and diagnosis of solid tumors.

A New Frontier in Cancer Therapy

The partnership's primary focus is on creating antibodies that incorporate a linker mechanism attached to the YB-800 compound. This technology enables the inclusion of various radioactive isotopes to enhance the capabilities of treatment and diagnostics for patients facing solid tumors. By leveraging the potential of these radiolabeled antibodies, physicians can improve diagnostic procedures via SPECT imaging, concurrently acting on tumors that may not respond to conventional therapies. This approach represents a significant step forward in personalized cancer treatment strategies.

Dr. Peter Schiemann, the CEO of Ymmunobio and Chair of its Board, emphasizes the validation brought by Innosuisse, stating, "This support confirms our innovative methodology in targeting solid tumors and aims to enhance patient outcomes through advanced therapeutic and diagnostic solutions. We are thrilled not only for the recognition but also for having PSI as an exceptional partner in developing these treatments. Together, we are forging new paths in oncology to ensure a future of personalized, precise, and effective healthcare for all patients."

Excitement at PSI

Dr. Martin Behe, who leads the project at PSI, shares similar enthusiasm about the collaboration: "Radiolabeled compounds for cancer treatment have garnered notable attention from medical professionals and the broader industry. Many of these therapeutic radiopharmaceuticals are now routinely utilized following successful clinical trials. Collaborating with Ymmunobio to develop a radiolabeled antibody aims to push these advancements further, improving cancer treatment outcomes. This initiative is made viable through the substantial support of Innosuisse."

Focused Research and Development

Ymmunobio is recognized for its commitment to pioneering oncology research, focusing on a target receptor that addresses an urgent need in solid tumor treatment. Currently entering pre-clinical development, Ymmunobio is dedicated to advancing three main cancer treatment options:

• - YB-800ADC: This system is crafted to carry up to eight payloads through a third-generation linker.
• - YB-800R1 and YB-800R2: These therapeutic and diagnostic antibodies are designed to contain radioactive isotopes in conjunction with PSI.
• - YB-800BS: A bi-specific antibody that engages T-Cells through an aCD3 mechanism.

The innovative platform being developed through this collaboration positions Ymmunobio at the forefront of cancer therapeutics. The focus remains on meeting the complexities of treating gastrointestinal (GI) cancers, a significant area of unmet medical needs.

In conclusion, the partnership between Ymmunobio and PSI embodies a promising advancement in the field of oncology. The commitment to utilizing advanced diagnostics alongside targeted therapies holds the potential to transform patient experiences and improve cancer care, paving the way for more effective and individualized treatment options in the future.